Vergote I - Search Results

1

Genomic changes in endometrial polyps associated with tamoxifen show no evidence for its action as an external carcinogen.

Dal Cin P, Timmerman D, Van den Berghe I, Wanschura S, Kazmierczak B, Vergote I, Deprest J, Neven P, Moerman P, Bullerdiek J, Van den Berghe H. Dal Cin P, et al. Among authors: vergote i. Cancer Res. 1998 Jun 1;58(11):2278-81. Cancer Res. 1998. PMID: 9622058

2

Meigs' syndrome with elevated serum CA 125 levels: two case reports and review of the literature.

Timmerman D, Moerman P, Vergote I. Timmerman D, et al. Among authors: vergote i. Gynecol Oncol. 1995 Dec;59(3):405-8. doi: 10.1006/gyno.1995.9952. Gynecol Oncol. 1995. PMID: 8522265 Review.

3

A realistic clinical perspective of tamoxifen and endometrial carcinogenesis.

Assikis VJ, Neven P, Jordan VC, Vergote I. Assikis VJ, et al. Among authors: vergote i. Eur J Cancer. 1996 Aug;32A(9):1464-76. doi: 10.1016/0959-8049(96)00184-0. Eur J Cancer. 1996. PMID: 8911103 Review.

4

Images in clinical medicine. Tamoxifen-induced endometrial polyp.

Timmerman D, Vergote I. Timmerman D, et al. Among authors: vergote i. N Engl J Med. 1996 Nov 28;335(22):1650. doi: 10.1056/NEJM199611283352205. N Engl J Med. 1996. PMID: 8929362 Free article. No abstract available.

5

Should tamoxifen users be screened for endometrial lesions?

Neven P, Vergote I. Neven P, et al. Among authors: vergote i. Lancet. 1998 Jan 17;351(9097):155-7. doi: 10.1016/S0140-6736(05)78216-7. Lancet. 1998. PMID: 9449866 No abstract available.

6

Controversies regarding tamoxifen and uterine carcinoma.

Neven P, Vergote I. Neven P, et al. Among authors: vergote i. Curr Opin Obstet Gynecol. 1998 Feb;10(1):9-14. doi: 10.1097/00001703-199802000-00003. Curr Opin Obstet Gynecol. 1998. PMID: 9484623 Review.

7

A randomized trial on the use of ultrasonography or office hysteroscopy for endometrial assessment in postmenopausal patients with breast cancer who were treated with tamoxifen.

Timmerman D, Deprest J, Bourne T, Van den Berghe I, Collins WP, Vergote I. Timmerman D, et al. Among authors: vergote i. Am J Obstet Gynecol. 1998 Jul;179(1):62-70. doi: 10.1016/s0002-9378(98)70294-7. Am J Obstet Gynecol. 1998. PMID: 9704766 Clinical Trial.

8

Tamoxifen and the uterus.

Vergote I, Neven P, Vanderick G, van Dam P, Van Belle Y, De Sutter Ph, De Prins F, De Muylder X, Claerhout J, Campo R, Albertyn G. Vergote I, et al. Eur J Cancer. 1998 Aug;34 Suppl 4:S1-3. doi: 10.1016/s0959-8049(98)00174-9. Eur J Cancer. 1998. PMID: 9917139 No abstract available.

9

Subjective assessment of adnexal masses with the use of ultrasonography: an analysis of interobserver variability and experience.

Timmerman D, Schwärzler P, Collins WP, Claerhout F, Coenen M, Amant F, Vergote I, Bourne TH. Timmerman D, et al. Among authors: vergote i. Ultrasound Obstet Gynecol. 1999 Jan;13(1):11-6. doi: 10.1046/j.1469-0705.1999.13010011.x. Ultrasound Obstet Gynecol. 1999. PMID: 10201081 Free article.

10

Artificial neural network models for the preoperative discrimination between malignant and benign adnexal masses.

Timmerman D, Verrelst H, Bourne TH, De Moor B, Collins WP, Vergote I, Vandewalle J. Timmerman D, et al. Among authors: vergote i. Ultrasound Obstet Gynecol. 1999 Jan;13(1):17-25. doi: 10.1046/j.1469-0705.1999.13010017.x. Ultrasound Obstet Gynecol. 1999. PMID: 10201082 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

882 results

Search Page

Filters